---
title: "CSPC says Innovation unit files new Hong Kong listing application after prior lapse"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290406575.md"
description: "CSPC Pharmaceutical Group announced that its subsidiary, CSPC Innovation, filed a new application for an H-share listing on the Hong Kong Stock Exchange on June 18, 2026. This follows the lapse of a previous filing. The offering details remain undecided, and completion depends on regulatory approvals from China's CSRC and Hong Kong authorities."
datetime: "2026-06-22T08:39:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290406575.md)
  - [en](https://longbridge.com/en/news/290406575.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290406575.md)
---

# CSPC says Innovation unit files new Hong Kong listing application after prior lapse

-   CSPC Pharmaceutical Group updated markets on a proposed H-share listing of subsidiary CSPC Innovation. \* CSPC Innovation filed a fresh listing application with the Hong Kong Stock Exchange on June 18, 2026, following the lapse of a prior filing. \* CSPC expects CSPC Innovation to remain an indirect subsidiary if the listing completes. \* Offering size, structure, pricing, timetable remain undecided. \* Completion hinges on regulatory clearances, including China’s CSRC, Hong Kong’s Stock Exchange, and the SFC. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12209989), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC Pharmaceutical changes trustee for 2018 share award scheme to BOCI Trustee Hong Kong](https://longbridge.com/en/news/295684438.md)
- [Weekly Recap: US$30M AstraZeneca upfront and SYS6063 Phase I start](https://longbridge.com/en/news/296034254.md)
- [CSPC says FDA clears US clinical trial for SYS 6037 mpox mRNA vaccine](https://longbridge.com/en/news/295395119.md)
- [CSPC Pharmaceutical receives USD 30 million upfront payment from AstraZeneca under siRNA pact](https://longbridge.com/en/news/295663654.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)